Compound: Granisetron (JAN/USAN/INN)
SMILES: O=C(N[C@@H]1C[C@H]2N(C)[C@@H](C1)CCC2)c3nn(C)c4c3cccc4
InChIKey: MFWNKCLOYSRHCJ-BTTYYORXSA-N
Synonyms: Granisetron (JAN/USAN/INN), RefChem:1086176, granisetron, 109889-09-0, Sancuso, Sustol, exo-Granisetron, Kevatril, BRL-43694, Granisetronum, APF530, 1364914-39-5, Kytril, 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide, APF 530, WZG3J2MCOL, BRL 43694, 1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide, CHEBI:5537, CHEMBL1290003, Granisetron EP Impurity F, 1-Methyl-N-[(1r,5s)-9-Methyl-9-Azabicyclo[3.3.1]nonan-3-Yl]indazole-3-Carboxamide, Granisetronum [INN-Latin], 1-Methyl-N-(9-methyl-endo-9-azabicyclo(3.3.1)non-3-yl)-1H-indazole-3-carboxamide, LY-278584, 1-methyl-N-((1R,3s,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1H-indazole-3-carboxamide, 1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo(3.3.1)non-3-yl)-, endo-, SR-05000001492, UNII-WZG3J2MCOL, BIDD:GT0272, APF-530, HMS2089P14, 1-Methyl-N-(9-methyl-endo-9-azabicyclo[3.3.1]non-3-yl)-1H-indazole-3-carboxamide, CWB, Granisetron [USAN:INN:BAN:JAN], Sancuso (TN), BRL 43964, Granisetron (Standard), Granisetron Impurity 22, GRANISETRON [MI], GRANISETRON [INN], GRANISETRON [JAN], GRANISETRON [USAN], GRANISETRON [VANDF], Granisetron (AB-1001), SCHEMBL4890, SCHEMBL4891, SCHEMBL34178, GRANISETRON [USP-RS], GRANISETRON [WHO-DD], CHEMBL399538, GTPL2300, DTXSID0023111, SCHEMBL30372601, CHEBI:94501, HY-B0071R, GRANISETRON [ORANGE BOOK], MFWNKCLOYSRHCJ-AGUYFDCRSA-N, 9-Azabicyclo[3.3.1]nonane, 1H-indazole-3-carboxamide deriv., GLXC-03029, HMS3715H17, HMS3886G11, GRANISETRON [USP MONOGRAPH], BDBM50443668, BDBM50449636, DL-166, EBC-03921, s5052, 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-indazole-3-carboxamide, AKOS025402424, AC-8910, CCG-221158, DB00889, NCGC00388522-02, FM137557, C07023, D04370, AB00918713-07, EN300-1715980, Q596708, SR-05000001492-1, SR-05000001492-2, Z1501485362, 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]nonan-7-yl)indazole- 3-carboxamide, 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-7-yl]indazole-3-carboxamide
Theoretical properties:
molecular_formula: C18H24N4O
molecular_weight: 312.4 g/mol
exact_mass: 312.19501140 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 2
heavy_atom_count: 23
topological_polar_surface_area: 50.2 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Granisetron is a monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 1-methyl-1H-indazole-3-carboxylic acid with the primary amino group of (3-endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine. A selective 5-HT3 receptor antagonist, it is used (generally as the monohydrochloride salt) to manage nausea and vomiting caused by cancer chemotherapy and radiotherapy, and to prevent and treat postoperative nausea and vomiting. It has a role as a serotonergic antagonist and an antiemetic. It is a monocarboxylic acid amide, a member of indazoles and a tertiary amino compound.
chebi: A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 1-methyl-1<em>H</em>-indazole-3-carboxylic acid with the primary amino group of (3-<i>endo</i>)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine. A selective 5-HT<small><sub>3</sub></small> receptor antagonist, it is used (generally as the monohydrochloride salt) to manage nausea and vomiting caused by cancer chemotherapy and radiotherapy, and to prevent and treat postoperative nausea and vomiting.
chembl: Unnamed Compound is a small molecule listed in the ChEMBL database but has not progressed to an approved clinical phase.
wikipedia: Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs. In most circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are international nonproprietary names (INNs); and trade names, which are brand names. Under the INN system, generic names for drugs are constructed out of affixes and stems that classify the drugs into useful categories while keeping related names distinguishable. A marketed drug might also have a company code or compound code.